Fig. 6. In vivo peritoneal distribution and efficacy of PGC–PTX NPs as a single dose. Three weeks after IP tumor inoculation, mice received either (a) rhodamine or (b) PGC–PTX-Rho NPs at equivalent rhodamine doses. Three days after injection, the peritoneum was assessed under (left) ambient and (right) ultraviolet light. The largest IP tumors are circled in yellow in each image. PGC–PTX-Rho NPs are visualized primarily in areas of tumor under ultraviolet light. PGC–PTX NP efficacy was evaluated in a prevention of peritoneal mesothelioma establishment model in which animals (n = 8/group) received MSTO-211H-luc cells followed by same-day treatment. (c) Cumulative survival and (d) tumor burden of animals treated with PGC–Bn NPs, 20 mg kg^–1 PTX-C/E, daily 20 mg kg^–1 PTX-C/E for 7 days, weekly 20 mg kg^–1 PTX-C/E for 7 weeks, or 140 mg kg^–1 PTX via 34% PGC–PTX NPs. PGC–PTX NP efficacy was also evaluated in the treatment of established peritoneal mesothelioma. (e) Cumulative survival and (f) tumor burden of animals treated with saline, PGC–Bn NPs, weekly 20 mg kg^–1 PTX-C/E for 7 weeks, or 140 mg kg^–1 PTX via 34% PGC–PTX NPs. Bioluminescence data is presented as the mean ± standard deviation for 3 randomly assigned animals per group.